Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Lefitolimod for extensive small cell lung cancer – maintenance therapy. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Small cell lung cancer is a fast growing and rare type of lung cancer, which is usually caused by smoking. Treatment of small cell lung cancer is often successful at first, but usually the cancer returns and spreads to other parts of the body.
Lefitolimod is a new drug for the treatment of extensive small cell lung cancer that is injected under the skin. Some studies have suggested that lefitolimod may be helpful for people who have responded to their first treatment that may stop or delay the cancer coming back. More studies are now aiming to show how well it works and that it is safe to use.
If lefitolimod is licensed for use in the UK, it could be a new treatment option for extensive small cell lung cancer that may improve survival and quality of life when current treatments have stopped working. Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Small Cell Lung Carcinoma Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000676 Date abstract record published 11/05/2016 |